Novartis Targets 5% Annual Sales Growth Through 2031
Novartis expects 5% constant-currency annual sales growth through 2031 and lifted peak-sales guidance for three drugs to a combined $18 billion.

KEY TAKEAWAYS
- Novartis expects 5% constant-currency annual sales growth from 2026 through 2031.
- Peak-sales guidance for Kesimpta, Scemblix and Leqvio rose to a combined $18 billion.
- Novartis cited 35 or more potentially submission-enabling readouts through 2031.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
Novartis (NVS) said on Nov. 19, 2026, that it expects net sales to grow at a 5% constant-currency compound annual rate from 2026 through 2031, and raised peak-sales guidance for Kesimpta, Scemblix and Leqvio to a combined $18 billion.
Three Drugs Lift Peak Sales Guidance
Novartis raised peak-sales guidance for Kesimpta to $6 billion to $8 billion, for Scemblix to $4 billion to $5 billion and for Leqvio to $4 billion to $5 billion. The three revised forecasts were previously a combined $14 billion.
The move followed a recent increase in peak-sales guidance for Rhapsido, also known as remibrutinib, to $8 billion across chronic spontaneous urticaria, chronic inducible urticaria and relapsing multiple sclerosis. Novartis said nine in-market assets now have peak-sales potential of $3 billion to $10 billion each, including Kisqali, Rhapsido, Cosentyx, Kesimpta, Pluvicto, Scemblix, Leqvio, the Zolgensma Group and Fabhalta. The company has pointed to existing brands as a source of growth alongside upcoming launches.
Pipeline Readouts Support Longer-Term Growth
Novartis identified 35 or more potentially submission-enabling readouts through 2031 and more than 30 potential high-value pipeline assets across four core therapeutic areas and three technology platforms. Ten late-stage assets were described as having multi-billion-dollar peak-sales guidance.
Management said, "Our full Phase I and II pipeline gives us further confidence that we can sustain mid-single-digit growth over the longer term." The company is also scaling artificial intelligence across research, development, manufacturing and commercial operations, though it did not quantify efficiency gains.
Novartis named pricing pressure, patent loss, clinical outcomes, technology adoption and reimbursement among material risks to its outlook. It also said core operating-income margin is on track to return to more than 40% by 2029.





